NASDAQ$ANAB
Anaptysbio Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
AnaptysBio reported its fourth quarter and full year 2024 financial results, highlighting positive Phase 2b data for rosnilimab in rheumatoid arthritis and a strong cash position.
AnaptysBio announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, showing impressive safety, tolerability, and efficacy. The company reported a net loss of $21.8 million for Q4 2024, with collaboration revenue of $43.1 million. Cash and investments stood at $420.8 million at year-end 2024, with a reiterated cash runway through year-end 2027.
- Rosnilimab achieved positive results from its Phase 2b rheumatoid arthritis trial, demonstrating highest-ever reported CDAI LDA response over 6 months.
- Top-line Phase 2 data for rosnilimab in ulcerative colitis is now anticipated in Q4 2025, moved up from previous expectations.
- AnaptysBio entered an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, receiving $15 million upfront.
- The company ended 2024 with approximately $420.8 million in cash and investments, reiterating a cash runway through year-end 2027.
Headline financials
Revenue & EPS history
Anaptysbio · Revenue · Quarterly
$43.1M
Forward guidance
AnaptysBio anticipates reporting full clinical and translational data for rosnilimab in RA in Q2 2025 and top-line Phase 2 data for rosnilimab in UC in Q4 2025. The company expects to initiate a Phase 1a trial for ANB101 in Q1 2025 and disclose the Phase 1b indication for ANB033 at a 2025 R&D event. GSK anticipates top-line data from COSTAR Lung Phase 3 trial in H1 2025 and AZUR-1 pivotal Phase 2 trial in 2026.
Tailwinds
- Full clinical and translational data for rosnilimab in RA expected in Q2 2025.
- Top-line Phase 2 data for rosnilimab in UC moved up to Q4 2025.
- Phase 1a trial for ANB101 to initiate in Q1 2025.
- Potential for future regulatory approvals and sales milestones from Vanda Pharmaceuticals agreement.
- Potential for additional milestones and royalties from GSK collaboration.
Headwinds
- No specific negative forward guidance was provided in the report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-1.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-2.2%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+15.8%
Q4 2019
Best reaction
-71.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -7.0% | -20.1% | |
| Q4 2025 | +14.5% | +13.0% | +9.2% | |
| Q3 2025 | +3.5% | -2.2% | +27.7% | |
| Q1 2025 | +0.9% | +2.6% | +18.2% | |
| Q4 2024 | +4.8% | +2.1% | +15.5% | |
| Q3 2024 | +11.4% | +6.9% | +18.7% | |
| Q2 2024 | -2.1% | +0.9% | +13.3% | |
| Q1 2024 | -9.1% | -1.9% | -9.0% | |
| Q4 2023 | +5.1% | -5.4% | -10.6% | |
| Q3 2023 | +6.0% | -0.1% | -9.3% | |
| Q2 2023 | +1.3% | +1.6% | +6.5% | |
| Q1 2023 | -9.5% | -13.3% | -12.9% | |
| Q4 2022 | -1.4% | -5.1% | -12.6% | |
| Q3 2022 | +0.7% | +6.5% | -3.0% | |
| Q2 2022 | -6.2% | +6.2% | +7.0% | |
| Q1 2022 | -11.6% | -10.1% | -14.3% | |
| Q4 2021 | -3.5% | -5.4% | -14.6% | |
| Q3 2021 | +8.9% | +2.9% | -11.2% | |
| Q2 2021 | -1.0% | +0.4% | +15.0% | |
| Q1 2021 | +3.0% | +10.5% | +0.6% | |
| Q4 2020 | +8.4% | +4.2% | -19.9% | |
| Q3 2020 | -1.5% | -0.3% | -18.7% | |
| Q2 2020 | -5.6% | -8.4% | -14.4% | |
| Q1 2020 | +0.2% | +13.0% | +10.3% | |
| Q4 2019 | +15.8% | +21.9% | -11.0% | |
| Q3 2019 | -71.3% | -69.6% | -61.2% | |
| Q2 2019 | -1.4% | -5.2% | -20.5% | |
| Q1 2019 | -6.8% | -0.7% | -3.5% | |
| Q4 2018 | -1.6% | -4.4% | +1.8% | |
| Q3 2018 | -16.1% | -19.0% | -16.5% | |
| Q2 2018 | +4.6% | +6.8% | +10.2% | |
| Q1 2018 | +0.5% | +0.6% | -18.8% | |
| Q4 2017 | -6.6% | -9.1% | -26.6% | |
| Q3 2017 | +1.3% | +2.7% | +37.1% | |
| Q2 2016 | +0.8% | -5.2% | +46.0% | |
| Q2 2017 | +0.8% | -5.2% | +46.0% | |
| Q1 2016 | -1.1% | +0.2% | -15.9% | |
| Q4 2016 | -1.1% | +7.4% | -12.4% | |
| Q1 2017 | +2.5% | +7.4% | -12.4% | |
| Q3 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro